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Hepatitis C virus (HCV) is a global challenge to public health. Several factors have been proven to be critical
for HCV entry, including the newly identified claudin-1 (CLDN1). However, the mechanism of HCV entry is
still obscure. Presently, among the 20 members of the claudin family identified in humans so far, CLDN1 has
been the only member shown to be necessary for HCV entry. Recently, we discovered that Bel7402, an
HCV-permissive cell line, does not express CLDN1 but expresses other members of claudin family. Among
these claudins, CLDN9 was able to mediate HCV entry just as efficiently as CLDN1. We then examined if other
members of the claudin family could mediate entry. We show that CLDN6 and CLDN9, but not CLDN2,
CLDN3, CLDN4, CLDN7, CLDN11, CLDN12, CLDN15, CLDN17, and CLDN23, were able to mediate the entry
of HCV into target cells. We found that CLDN6 and CLDN9 are expressed in the liver, the primary site of HCV
replication. We also showed that CLDN6 and CLDN9, but not CLDN1, are expressed in peripheral blood
mononuclear cells, an additional site of HCV replication. Through sequence comparison and mutagenesis
studies, we show that residues N38 and V45 in the first extracellular loop (EL1) of CLDN9 are necessary for
HCV entry.
Hepatitis C virus (HCV) is the major cause of liver cirrhosis
and hepatocellular carcinoma worldwide. Approximately 3%
of the global population is infected with HCV, and at least
70% develop chronic hepatitis (13, 17, 32). In patients with
chronic HCV infection, about 20% develop liver cirrhosis,
about 5% of which go on to develop hepatocellular carcinoma
(17). While HCV is generally confined to the liver, there is
growing evidence suggesting that HCV can replicate in extra-
hepatic tissues including peripheral blood mononuclear cells
(PBMCs) (4, 15, 23, 24).
HCV is a small, enveloped virus that belongs to the family
Flaviviridae (19). Its genome encodes an approximately 3,000-
amino-acid precursor polyprotein, which is cleaved into at least
10 mature proteins, including two envelope glycoproteins.
These glycoproteins are referred to as E1 and E2 (25). E2 is
believed to interact with putative receptors on the surface of
target cells (29). CD81 has been shown to interact with the E2
glycoprotein and can serve as a coreceptor for HCV entry of all
six genotypes (1, 2, 6, 14, 18, 21, 26, 34, 36). In addition,
scavenger receptor class B member I (SR-BI) is another E2
binding protein and was shown to enhance HCV entry in a
high-density-lipoprotein-dependent manner (3, 18, 31, 35).
However, the overexpression of both CD81 and SR-BI was not
able to render nonhepatic cells susceptible to HCV (2, 37).
Recently, Evans et al. reported that claudin-1 (CLDN1), an
integral membrane protein and a component of tight-junction
strands, was able to mediate the entry of HCV in two nonhe-
patic cell lines, 293T and SW13. In addition, CLDN1 acts after
virus binding with CD81 and is most likely important for
mediating the fusion between the viral and cellular lipid mem-
branes (7). However, there are several cell lines that are resis-
tant to HCV infection which express CLDN1, CD81, and SR-
BI. The existence of such cell lines indicates that other factors
are required for HCV entry in addition to the previously iden-
tified receptors (7).
The claudin family constitutes a large group of four-trans-
membrane domain proteins that are essential for the forma-
tion of tight junctions (22). Tight junctions are responsible for
the control of paracellular transport and maintenance of cell
polarity (10). To date, 20 claudins have been identified in
humans according to UniGene (http://www.ncbi.nlm.nih.gov
/sites/entrez?db"unigene). Most tissues express various clau-
din proteins, and these proteins interact with each other ho-
mologously or heterologously to form the tight-junction
strands (9). Variations in tight junctions are most likely deter-
mined by combinations of constituent claudins. Members of
the claudin family are highly conserved, especially in the first
extracellular loop (EL1), which was found to be important for
the interaction with HCV (7). It has also been reported that
liver expresses multiple claudins (28). This result suggests that
other claudins, in addition to CLDN1, might be able to medi-
ate HCV entry.
Here, we show that the human hepatocellular carcinoma cell
line Bel7402 is susceptible to HCV but that it does not express
CLDN1. CLDN9 expression in Bel7402 cells was found to
mediate HCV entry. Furthermore, its closest relative, CLDN6,
was shown to function similarly. The expression of CLDN6 and
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CLDN9 in the liver, where HCV replicates the most, was
detected. In addition, PBMCs, the extrahepatic tissue believed
to be a site of HCV replication, were shown to express CLDN6
and CLDN9 but not CLDN1. By sequence comparison and
mutational analysis, two residues, N38 and V45, were identi-
fied as being critical for HCV entry in CLDN9-expressing cells.
These data suggest that CLDN6 and CLDN9 can also mediate
HCV entry into target cells.
MATERIALS AND METHODS
Cells. 293T cells were used as packaging cell lines for the human immunode-
ficiency virus (HIV)-backboned pseudotyped particle preparation for the infec-
tion assay. 293GP cells were used as packaging cell lines for the pBabepuro-
backboned pseudotyped particles. 293T and SW13 cells were used as target cells
to construct cell lines stably expressing claudins. Hep3B, Huh7, PLC/PRF/5,
Bel7402, SMMC7721, U87, and HeLa human cell lines were used for virus
infection assays. All these cells were grown in Dulbecco’s modified Eagle me-
dium supplemented with 10% fetal bovine serum (Gibco). PBMCs were isolated
from fresh peripheral blood on lymphocyte separation medium (Ficoll-Paque;
Amersham Biosciences) by centrifugation at 400 # g.
Reverse transcription (RT)-PCR. Total RNA of cells or tissues was isolated
with TRIzol reagent (Life Technologies) and reverse transcribed using a Re-
verse-Transcribe kit (CY-TECH, China). The resulted cDNA were amplified by
Ex Taq polymerase (Takara, Japan) using claudin-specific primers with GAPDH
as a control. The primer sequences of claudins are available upon request.
Plasmids. DNA fragments containing a Kozak sequence and the complete
open reading frame of claudins were amplified from cDNA from Bel7402 cells,
Huh7 cells, or liver and cloned into a BamHI/SalI (New England Biolabs)-
digested pBabepuro vector. Flag-tagged claudins were constructed similarly, with
the reverse primers containing a Flag tag sequence. Point mutations in CLDN3,
CLDN6, and CLDN9 were generated by site-directed mutagenesis using a
QuikChange kit (Stratagene).
Generating stable cell lines that express various claudin variants.A retroviral
vector expressing claudin variants was transfected together with a plasmid
encoding the vesicular stomatitis virus glycoprotein (VSV-G) into 293GP
cells, a cell line that stably expresses a lentiviral gag-pol gene, using a calcium
phosphate precipitation protocol. The supernatants were harvested 48 h later
and used to infect 293T and SW13 cells. Forty-eight hours after infection, the
cells were selected in medium containing puromycin (Sigma) at 5 $g/ml for at
least 1 week.
Real-time PCR. The primes for CLDN1, CLDN6, CLDN9, and GAPDH were
designed by using PRIMEREXPRESS software (version 2.0; Applied Biosystems)
crossing intron-exon boundaries. For standardization of the amount of mRNA,
expression ofGAPDH in each sample was also quantified. All PCRs were performed
using an ABI Prism 7000 sequence detector (Perkin-Elmer Applied Biosystems) as
described previously (27). Briefly, equivalent amounts of cDNA sample, derived
from 50 ng of DNase-digested total RNA, were used for each PCR. The threshold
cycle values were determined using the AUTOANALYSE features of Sequence
Detection System software. The primers were as follows: 5%-GCG CGA TAT TTC
TTC TTG CAG-3% (CLDN1 forward), 5%-GCA GGT TTT GGA TAGGGC CT-3%
(CLDN1 reverse), 5%-AGA AGG ATT CCA AGG CCC G-3% (CLDN6 forward),
5%-GATGTTGAGTAGCGGGCCAT-3% (CLDN6 reverse), 5%-GCGGCTGCA
CTG CTT ATG CT-3% (CLDN9 forward), 5%-GCA GTG GGG AGC AGT GGG
CT-3% (CLDN9 reverse), 5%-CTC AAC TAC ATG GTC TAC AT-3% (GAPDH
forward), and 5%-AGT AGA CTC CAC GAC ATA CT-3% (GAPDH reverse).
Quantitative PCR was performed in duplicate for each sample, and three indepen-
dent experiments were carried out. The means and standard deviations (SD) were
calculated and reported as data from one representative experiment.
Pseudotyped particle generation and infection assays.HIV/HCV pseudotyped
particles (HCVpp) were produced as described previously (14). Briefly, 12 $g
pNL4-3.luc.R&E& and 12 $g HCV envelope glycoproteins expressing plasmids
were cotransfected into 293T cells using a calcium phosphate precipitation pro-
tocol. Empty vector or plasmid expressing VSV-G was used as a control. The
medium was replaced 12 h after transfection. Supernatants were harvested 36 h
later, cleared by centrifugation, and used for the infection assay. In this paper,
HCVpp refers to pseudotyped particles bearing envelope glycoproteins of strain
H77 unless otherwise stated.
Target cells (8# 103 cells per well) were seeded into 96-well plates 24 h before
infection. Pseudotyped particles (5 ng HIV-1 p24 for HCVpp and no env and 0.1
ng for VSV-G) plus 8 $g/ml polybrene were incubated with cells for 3 h at 37°C
and then replaced with fresh medium. The cells were lysed 48 h after infection,
and 30 $l of lysates was tested for luciferase activity by the addition of 50 $l
luciferase substrate (Promega) on a Beckman LD400 luminometer (Beckman-
Coulter). Infection was performed in triplicate for each sample. Similar results
were obtained in three independent experiments.
Cell culture-derived HCV and infection assay. A plasmid containing the
genome of chimeric J6/JFH with a T7 promoter was linearized by XbaI
digestion and in vitro transcribed using a MEGAscript T7 kit (Ambion).
Huh7.5 cells were electroporated with RNA using an electroporator (Bio-
Rad), and the supernatants were collected 72 h later. High-titer stocks were
gained by passage on fresh Huh7.5 cells three times. The supernatants were
titrated on Huh7.5 cells by a limiting-dilution assay as described previously
(19). Huh7.5 cells and naive and claudin-expressing 293T cells were seeded in
a four-well plate 24 h before infection. Cells were tested for the presence of
J6/JFH RNA by real-time PCR 72 h after infection. The primers were as
FIG. 1. Lack of expression of CLDN1 in the HCV-susceptible cell line Bel7402. (A) Cell tropism of HCVpp and its correlation to expression
of CLDN1. Different cell lines were infected by HCVpp-bearing envelope glycoproteins of strain H77 (gray bar), and luciferase activity was
measured as relative light units (RLU) 48 h postinfection. Pseudotyped particles containing VSV-G protein (black bars) or in the absence of
envelope protein (white bars) were used as a control (mean of n " 3) (error bars indicate SD). Expression of CLDN1 in these cell lines was
analyzed by semiquantitative RT-PCR and is shown under the bar graph, with GAPDH as a control. (B) Expression pattern of known human
claudins in Bel7402 cells. The expression of known claudins in Bel7402 cells was analyzed by semiquantitative RT-PCR, usingGAPDH as a control.
&RT, control reaction of cDNA synthesis in which reverse transcriptase was not added.
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follows: 5%-CTT CAC GCA GAA AGC GTC T-3% (forward) and 5%-CAA
GCA CCC TAT CAG GCA G-3% (reverse).
RNA interference. RNA interference was performed using lentivirus-delivered
short hairpin RNAs (shRNAs) as described previously (30). Briefly, vector
pLL3.7 expressing shRNAs targeting the CLDN9 reference sequence (GenBank
accession number NM_020982) was transfected into 293T cells together with
three package plasmids. The resulting supernatants were collected 48 h after
transfection and used to infect Bel7402 cells. The expression level of CLDN9 in
infected cells was determined by real-time PCR 96 h after infection withGAPDH
as a control. The shRNA sequences were designed by siSearch (http://sonnhammer
.cgb.ki.se/siSearch/siSearch_1.7.html): 5%-GAC TACGAG TCTGCT TTG T (342),
5%-GGA AGG TGA CCG CCT TCA T (661), and 5%-TAG CAG CTA AAC ACA
TCA A (irrelevant control).
Antibodies and Western blotting. Mouse anti-Flag M2 monoclonal antibody
was purchased from Sigma. Rabbit anti-human CLDN9 polyclonal antibody was
purchased from Genway Biotech. Horseradish peroxidase-labeled anti-human
GAPDH (glyceraldehyde-3-phosphate dehydrogenase) monoclonal antibody
and anti-mouse and anti-rabbit secondary antibodies were purchased from New
England Biolabs. fifty micrograms of total protein was separated by a 12%
sodium dodecyl sulfate-polyacrylamide gel, which was followed by transfer onto
a nitrocellulose membrane (Hybond ECL; GE), and stained with a primary
antibody and a horseradish peroxidase-labeled secondary antibody. Naive 293T
cells served as a control. The bands were detected by an ECL plus kit (GE).
RESULTS
Identification of CLDN6 and CLDN9 as HCV coreceptors.
To test whether the newly identified HCV coreceptor CLDN1
is involved in HCV infection of all susceptible cell lines, the
association between HCVpp susceptibility and CLDN1 expres-
sion was examined in several known HCV-nonpermissive and
-permissive cell lines. Three HCV-permissive cell lines, Huh7,
Hep3B, and PLC/PRF/5, expressed CLDN1. In contrast, all
three cell lines that could not be infected by HCVpp (U87,
HeLa, and L02) did not show detectable levels of CLDN1 (Fig.
1A). In addition, we also tested another hepatocellular carci-
noma cell line, Bel7402, which was derived from a Chinese
FIG. 2. CLDN6 and CLDN9 mediate HCVpp entry. (A) 293T cells stably expressing claudins that were found in the Bel7402 cell line were infected
with pseudotyped particles harboring VSV-G protein (black bar), envelope glycoproteins of HCV strain H77 (gray bars), and no env (white bars), with
luciferase as a reporter (RLU, relative light units) (mean of n " 3) (error bars indicate SD). Naive 293T cells were used as a negative control.
(B) Expression level ofCLDN9 in Bel7402 cells treated withCLDN9-specific or irrelevant (irr.) shRNAs was determined by real-time PCR usingCLDN9-
and GAPDH-specific primers. The value of GAPDH was initialized to 1 (mean of n " 2) (error bars indicate SD). (C) Bel7402 cells treated with
CLDN9-specific shRNAs were infected by pseudotyped particles bearing envelope glycoproteins as indicated in A. Results are presented as percentages
of infection in irrelevant shRNA-treated cells (irr.) (mean of n " 3) (error bars indicate SD). (D) High homology between CLDN6 and CLDN9. The
phylogenetic tree of EL1 of claudin family members was created by DNAMAN. The homology among EL1 of claudin family members is indicated as
a percentage. (E) CLDN6 could also mediate HCVpp entry. Huh7, naive 293T, and 293T cells stably expressing individual CLDN1, CLDN6, CLDN9,
CLDN2, CLDN3, CLDN4, CLDN7, CLDN11, CLDN12, CLDN15, CLDN17, and CLDN23 were infected with luciferase reporter viruses pseudotyped
with envelope glycoproteins indicated as in A (RLU, relative light units) (mean ofn" 3) (error bars indicate SD). (F) Flag-tagged CLDN9 could mediate
HCV entry as efficiently as naive CLDN9. CLDN9-expressing and CLDN9-Flag-expressing 293T cells were infected by pseudotyped particles bearing
envelope glycoproteins, as indicated in A, with luciferase as a reporter (mean of n " 3) (error bars indicate SD). The expression of CLDN9 and
CLDN9-Flag was detected by Western blotting using antibodies against CLDN9 and Flag tag, with GAPDH as a control.
VOL. 81, 2007 CLDN6 AND CLDN9 MEDIATE HCV ENTRY 12467
 at UNIV OF BIRM
INGHAM
 on June 17, 2008 
jvi.asm
.org
Downloaded from
 
hepatocellular carcinoma patient (5, 20, 33, 38). As shown in
Fig. 1A, Bel7402 is permissive to HCVpp, but interestingly, no
expression of CLDN1 was detected by RT-PCR. This suggests
that factors other than CLDN1 could facilitate HCV entry.
According to the UniGene database for Homo sapiens, at
least 20 members of the claudin family have been identified.
Therefore, it was reasonable to assume that claudins other
than CLDN1 might also serve as coreceptors for HCV. Intrigu-
ingly, RT-PCR analysis revealed that among the 20 known
claudins examined, CLDN2, CLDN7, CLDN9, CLDN12,
CLDN17, and CLDN23 could be detected in Bel7402 cells at
various levels (Fig. 1B). This led to the subsequent study of
associations between HCV susceptibility and each of these
claudins. As described in Materials and Methods, cDNAs of
these claudins were cloned into retroviral vectors and used to
generate individual stable cell lines, where each would have
specific CLDN2, CLDN7, CLDN9, CLDN12, CLDN17, or
CLDN23 expression. These cell lines were challenged with
HCVpp, and, as shown in Fig. 2A, only CLDN9-expressing
293T cells could be infected by HCVpp as efficiently as cells
that expressed CLDN1 (Fig. 2A). Similar results were also
obtained in SW13 cells generated to have stable CLND9 ex-
pression (data not shown). To further confirm the role of
CLDN9 in HCVpp infection, we performed RNA interference
to reduce endogenous CLDN9 expression. Two shRNA se-
quences targeting CLDN9 (referred to as 342 and 661) were
delivered into Bel7402 cells using a lentivirus-based system. As
shown in Fig. 2B, the expression level of CLDN9 in 342- and
661-treated cells was significantly downregulated compared
with the irrelevant shRNA-treated cells. The susceptibility of
these CLDN9-silencing cells to HCVpp, but not to VSV-Gpp,
was remarkably reduced (Fig. 2C). These data clearly demon-
strate that besides CLDN1, CLDN9 was also able to mediate
HCV entry into target cells.
It has been reported that EL1 of CLDN1 was critical for
mediating the interaction with HCV envelope glycoproteins
(7). To examine if there is any other claudin that might also
function as an HCV coreceptor, the amino acid sequences of
EL1 of all claudins were aligned to search for any similarities
with EL1 of CLDN9. Results showed that CLDN6, followed by
CLDN3 and CLDN4, demonstrated the highest order of ho-
mology for EL1 compared with CLDN9 (Fig. 2D). In contrast,
CLDN12, CLDN23, CLDN11, and CLDN15 showed the least
homology with CLDN9. Hence, CLDN3, CLDN4, and CLDN6
were selected for further functional experiments. In addition,
two other claudins with the least homology, CLDN11 and
CLDN15, were used as controls. The potential of these clau-
dins as HCV coreceptors was investigated using a method
similar to the methods described above. As shown in Fig. 2E,
the cell lines stably expressing CLDN6 could be efficiently
infected by HCVpp, therefore demonstrating that CLDN6 is
an additional claudin that is able to mediate the entry of HCV.
To monitor the expression of the claudin proteins in stable
cell lines, a Flag tag was fused to the C terminus of all of the
claudins studied (8). We show that all of these family members
were in fact expressed as expected. Furthermore, 293T cells
expressing Flag-tagged CLDN1, CLDN6, and CLDN9 were
susceptible to HCVpp, while the other Flag-tagged claudin
family members did not support HCV entry (CLDN9 is shown
in Fig. 2F, and the others are not shown). These results provide
further evidence that CLDN6 and CLDN9 are able to function
as HCV coreceptors.
The ability of CLDN6 and CLDN9 as HCV coreceptors was
further verified using cell culture-derived virus (HCVcc). Cell
culture-derived particles of J6/JFH were produced by the
transfection of Huh7.5 cells with in vitro-transcribed J6/JFH
RNA (19). To determine if the overexpression of CLDN6 and
CLDN9 could confer susceptibility of 293T cells to HCVcc, the
supernatants were harvested and used to inoculate 293T cells
that were either mock transfected or transfected with CLDN6
or CLDN9. The efficiency of infection was determined using
real-time PCR. Both CLDN6- and CLDN9-expressing 293T
cells support infection with HCVcc, but the titers of HCVcc on
these cells were about 400 times lower than those on Huh7.5
cells (Fig. 3), which might be a result of the inefficient repli-
cation of HCV in 293T cells (16).
No coreceptor usage preference among CLDN1, CLDN6,
and CLDN9 by various genotypes of HCV. HCV has been
classified into six genetically distinct genotypes exhibiting dif-
ferent phenotypic properties (1, 34). To investigate if there is
any preference in the coreceptor usage by HCV of various
genotypes, we generated a panel of HCVpp-bearing HCV en-
velope glycoproteins derived from six HCV strains (UKN1A
14.38, UKN2A 2.4, UKN3A 1.28, UKN4 11.1, UKN5 14.4, and
UKN6 5.340). These glycoproteins represented genotypes 1 to
6, respectively. Virus particles prepared with these glycopro-
teins were used to infect 293T cells expressing 12 claudin
family members including CLDN1 to CLDN4, CLDN6,
CLDN7, CLDN9, CLDN11, CLDN12, CLDN15, CLDN17
and CLDN23. Huh7 and parental 293T cells were used as
positive and negative controls. All of these HCVpps were un-
able to infect parental 293T cells and 293T cells expressing
claudins tested, with the exception of CLDN1, CLDN6, and
CLDN9 (data not shown). Although six genotypes of HCVpp
displayed different levels of infectivity in 293T cells expressing
CLDN1, CLDN6, and CLDN9, such differences in the effi-
ciency of infection are similar to that in Huh7 cells (data not
FIG. 3. CLDN6 and CLDN9 mediate HCVcc infection. HCVcc
infection was analyzed by real-time PCR. 293T cells expressing mock,
CLDN1, CLDN6, or CLDN9 were challenged with HCVcc of strain
J6/JFH. At 72 h postinfection, total RNAs were isolated from these
cells and amplified with primers specific to the corresponding claudins
or GAPDH. Huh7.5 cells were used as a positive control. The value of
GAPDH was initialized to 1 (mean of n " 2) (error bars indicate SD).
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shown), suggesting that there is no obvious preference in co-
receptor usage by various HCV genotypes.
Expression of CLDN6 and CLDN9 in liver, PBMCs, and
human hepatocellular carcinoma cell lines. Accumulating ev-
idence suggests that besides the liver, PBMCs are also impor-
tant target cells for HCV (4, 15, 23, 24). To study the in vivo
potential of the involvement of CLDN6 and CLDN9 in HCV
infection, the expression patterns of CLDN1, CLDN6, and
CLDN9 were examined in liver and PBMCs using real-time
PCR. These three claudin family members could be detected in
liver, implying that they might be all involved in HCV infection
in liver (Fig. 4). In PBMCs, CLDN6 and CLDN9, but not
CLDN1, could be detected. This result suggests that they may
be involved in mediating HCV entry into PBMCs. Further
experiments are needed to reveal their relevance in vivo. The
expression pattern of these three claudins was also studied in
several HCV-susceptible cell lines. As shown in Fig. 4, CLDN6
was expressed in Huh7 and HepG2 cells, while CLDN9 was
expressed in Bel7402 cells.
Identification of amino acid residues in CLDN9 critical for
HCV entry. Although CLDN3 shared the highest EL1 homol-
ogy to CLDN6 and CLDN9, it was unable to serve as an HCV
coreceptor. Comparison of EL1 sequences was carried out
between human CLDN1, CLDN3, CLDN6, and CLDN9 and
murine CLDN1. Four positions in the N terminus of EL1 were
selected for mutational analysis, namely, positions 38, 43, 45,
and 53 (CLDN9 was used as the reference sequence for num-
bering of the amino acid positions). At these sites, the non-
HCV receptor CLDN3 had residues that were different from
those of proposed HCV coreceptors (Fig. 5A). Since positions
32 and 48 have also been reported to be critical for CLDN1-
mediated HCV entry (7), they were selected as well. As
CLDN6 and CLDN9 are highly conserved in EL1 and differ
only at position 29, we first introduced a M29L mutation into
FIG. 4. Expression pattern of CLDN1, CLDN6, and CLDN9 in human liver, PBMCs, and human hepatocellular carcinoma cell lines. The
cDNA samples of different sources were amplified by real-time PCR using CLDN1 (A)-, CLDN6 (B)-, CLDN9 (C)-, and GAPDH-specific primers.
The value of GAPDH was initialized to 1 (mean of n " 2) (error bars indicate SD).
FIG. 5. Key residues in EL1 of CLDN9 necessary for HCVpp entry. (A) Alignment of the N-terminal EL1 amino acid sequences of human
CLDN1, CLDN3, CLDN6, and CLDN9 and murine CLDN1. Amino acid homology and differences are displayed by different shades of black.
Number represents the positions of amino acids in full-length CLDN9 that were selected as candidates for further analysis. The numbers for known
critical residues are shown in italics. (B and C) Wild-type and mutated claudin-transduced 293T cells were tested for susceptibility to HCVpp
bearing envelope glycoproteins of strain H77 (gray bar) or VSV-Gpp (black bar) with luciferase as a reporter (RLU, relative light units) (mean
of n " 3) (error bar indicate SD). (D and E) Expression of wild-type and mutated claudins was verified by real-time PCR. No signal was detected
on naive 293T cells. The value of GAPDH was initialized to 1 (mean of n " 2) (error bars indicate SD).
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CLDN6 and found no difference in levels of infectivity (data
not shown). After these mutations were introduced into
CLDN9 or CLDN3, they were delivered into 293T cells for
functional analysis. First, the expression of wild-type and mu-
tated claudins was confirmed by real-time PCR and showed no
obvious difference in expression levels among them (Fig. 5D
and E). As shown in Fig. 5B, A43S and S53N had no apparent
impact on CLDN9 coreceptor activity, while the N38S muta-
tion alone could mildly decrease CLDN9-mediated HCVpp
infection. Most strikingly, a single V45N mutation almost abol-
ished CLDN9-mediated HCVpp infection. Such effects of N38
and V45 were then further verified on CLDN3, in that a single
mutation of S38N or V45N in CLDN3 could partially render
293T permissive to HCVpp, while double mutations of S38N
and V45N could enhance this effect most significantly (Fig.
5B). V32M and E48K mutations displayed a similar effect on
CLDN9 (Fig. 5C) as on CLDN1 (7). Taken together, these
data demonstrated that besides V32 and E48, N38 and V45 are
critical for HCVpp entry in CLDN9, where V45 might play the
most important role during the process.
DISCUSSION
In this paper, we demonstrated that in addition to CLDN1,
CLDN6 and CLDN9 are able to mediate HCVpp and HCVcc
infection of nonhepatic cells, indicating that both claudins have
HCV coreceptor activity as well as CLDN1. The expression of
CLDN6 and CLDN9 in liver and PBMCs was detected, sug-
gesting their potential role in HCV infection in liver and the
extrahepatic compartment. Finally, we found two residues crit-
ical for HCV infection in EL1 of CLDN9.
The identification of CLDN6 and CLDN9 as additional
HCV coreceptors should assist in future efforts to understand
the relationship between claudin proteins and HCV pathogen-
esis. Representative strains of HCV genotypes 1 and 2 use
CLDN1 as a coreceptor, and CLDN1 is expressed at high
levels in liver (8), indicating its important role in HCV infec-
tion (7). Although the in vivo contribution of CLDN6 and
CLDN9 to HCV infection is unresolved, there are several lines
of evidence suggesting that CLDN6 and CLDN9 are potential
HCV coreceptors. Previous reports have shown that the ex-
pression of CLDN6 and CLDN9 in liver is detectable by RT-
PCR (11, 12). Our study also detected the expression of
CLDN6 and CLDN9 in liver by real-time PCR (Fig. 4). On the
other hand, the Huh7 and HepG2 human hepatocellular car-
cinoma cell lines were found to express both CLDN1 and
CLDN6, while Bel7402 expresses CLDN9 (Fig. 4). These data
suggest that CLDN6 and CLDN9 may play a role in HCV
infection in liver. Furthermore, we found CLDN6 and CLDN9
expressed in PBMCs, which are believed to be an HCV repli-
cation site outside the liver, whereas no expression of CLDN1
was detected by real-time PCR (Fig. 4). These results suggest
that CLDN6 and CLDN9 may also contribute to extrahepatic
HCV infection, especially in PBMCs.
Although HCV displays a high degree of genetic heteroge-
neity, no coreceptor usage preference was detected among
CLDN1, CLDN6, and CLDN9, which may be attributed to the
high similarity among their structures. Claudins are a family of
integral membrane proteins involved in the formation of tight
junctions. Tight junctions are responsible for the formation
and maintenance of the epidermal permeability barrier. Clau-
dins have three characteristic functional domains: (i) two ex-
tracellular loops responsible for permeability barrier formation
and EL1 with specific ion selectivity, (ii) four transmembrane
regions, and (iii) a cytoplasmic C tail that functions to anchor
to the cytoskeleton (9). Most of the claudin proteins display
high levels of homology, especially in CLDN6 and CLDN9.
These two claudin family members differ only at amino acid
position 29 in EL1. By aligning the amino acid sequences of
human CLND3, CLDN6, and CLDN9 and murine CLDN1, we
found four candidate residues that could play a role in medi-
ating HCV entry. By mutational analysis, we found that N38
and V45 are important for HCV infection in CLDN9 (Fig. 5B).
Residues at positions 32 and 48, critical for HCV infection in
cells that express CLDN1 (7), were also shown to be important
in CLDN9 in our studies (Fig. 5C). The identification of these
residues should be useful for the future development of drugs
that inhibit HCV infection.
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